Drug Profile
Carbon-11-PK-11195 - Genzyme
Alternative Names: (R)-[11C]PK11195; [11C]PK11195Latest Information Update: 24 Nov 2023
Price :
$50
*
At a glance
- Originator Sanofi
- Developer Ospedale San Raffaele; Sanofi; VU University Medical Center; Weill Cornell Medical College
- Class Diagnostic agents
- Mechanism of Action GABA A receptor modulators; Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Multiple sclerosis
- No development reported Alzheimer's disease; Brain disorders; Brain injuries
- Discontinued Coronary artery disease
Most Recent Events
- 11 Oct 2023 Clinical development is ongoing USA
- 11 Oct 2023 Efficacy data from a clinical trial in multiple sclerosis presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-2023)
- 07 Dec 2022 Discontinued - Phase-II for Coronary artery disease (Diagnosis) in Netherlands (IV)